On pharmacogenetic approaches to hypertension treatment in pregnant women
Ших Е. В., Жукова О. В., Остроумова О. Д., Шаронова С. С.
Акушерство и гинекология
Т. 2020, Вып. 2, С. 22-28
Опубликовано: 2020
Тип ресурса: Статья
DOI:10.18565/aig.2020.2.22-28
Аннотация:
Hypertension in pregnancy is an urgent problem of modern medicine due to its high prevalence (it occurs in 5–30[%] of pregnant women in the Russian Federation) and to the risk of maternal and fetal complications. Considering the complex and incompletely studied pathogenesis of hypertension during pregnancy, the selection of antihypertensive therapy (AHT) remains open and is now being actively studied. In recent years, prescription of AHT for pregnant women has come under consideration in the context of personalized medicine. The genetic characteristics of a patient, which affect a pharmacological response, are point mutations and the so-called single nucleotide polymorphisms. The existence of single nucleotide polymorphisms in one gene or another can define the genetically determined contribution to an individual’s pharmacological response. Endothelial dysfunction that is manifested inter alia by decreased nitric oxide (NO) synthesis is an important pathogenetic element in the developmen
Ключевые слова:
Antihypertensive therapy; Gestational hypertension; Hypertension; Pharmacogenetics; Preeclampsia; Pregnancy
antihypertensive agent; nicotinamide phosphoribosyltransferase; nitric oxide; vasculotropin; antihypertensive therapy; Article; endothelial dysfunction; female; gene interaction; genetic trait; human; maternal hypertension; pathogenesis; personalized medicine; pharmacogenetics; point mutation; preeclampsia; pregnant woman; prevalence; single nucleotide polymorphism
Язык текста: Русский
ISSN: 0300-9092
Ших Е. В. Евгения Валерьевна 1962-
Жукова О. В.
Остроумова О. Д. Ольга Дмитриевна 1968-
Шаронова С. С. Светлана Сергеевна 1997-
Shikh E. V. Evgeniya Valeryevna 1962-
Zhukova O. V.
Ostroumova O. D. Ol`ga Dmitrievna 1968-
Sharonova S. S. Svetlana Sergeevna 1997-
On pharmacogenetic approaches to hypertension treatment in pregnant women
Текст визуальный непосредственный
Акушерство и гинекология
Бионика Медиа
Т. 2020, Вып. 2 С. 22-28
2020
Статья
Antihypertensive therapy Gestational hypertension Hypertension Pharmacogenetics Preeclampsia Pregnancy
antihypertensive agent nicotinamide phosphoribosyltransferase nitric oxide vasculotropin antihypertensive therapy Article endothelial dysfunction female gene interaction genetic trait human maternal hypertension pathogenesis personalized medicine pharmacogenetics point mutation preeclampsia pregnant woman prevalence single nucleotide polymorphism
Hypertension in pregnancy is an urgent problem of modern medicine due to its high prevalence (it occurs in 5–30[%] of pregnant women in the Russian Federation) and to the risk of maternal and fetal complications. Considering the complex and incompletely studied pathogenesis of hypertension during pregnancy, the selection of antihypertensive therapy (AHT) remains open and is now being actively studied. In recent years, prescription of AHT for pregnant women has come under consideration in the context of personalized medicine. The genetic characteristics of a patient, which affect a pharmacological response, are point mutations and the so-called single nucleotide polymorphisms. The existence of single nucleotide polymorphisms in one gene or another can define the genetically determined contribution to an individual’s pharmacological response. Endothelial dysfunction that is manifested inter alia by decreased nitric oxide (NO) synthesis is an important pathogenetic element in the developmen